EMA/CVMP发布热灭活活体免疫兽药中内源性逆转录病毒反思文件修订版1(EMA/CVMP/IWP/37924/2014-Rev.1)
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products - Revision 1
EMA/CVMP于2026年11月5日通过反思文件修订版1(EMA/CVMP/IWP/37924/2014-Rev.1),该文件替代2014年原版,实施日期为2027年5月5日。
PDF 文字版;图形和原始排版请参阅官方 PDF。
第 1 页
13 November 2026
EMA/CVMP/IWP/37924/2014-Rev.1*
Committee for Veterinary Medicinal Products (CVMP)
Reflection paper on the use of heat treatment to
inactivate endogenous retroviruses in live immunological
veterinary medicinal products (IVMPs)
Adoption by Committee for Veterinary Medicinal Products
10 September 2015
(CVMP)
Revised reflection paper (revision 1) agreed by Immunologicals
18 September 2026
Working Party (IWP)
Adopted by CVMP 5 November 2026
Implementation date 5 May 2027
* This reflection paper replaces the Reflection paper on the use of heat treatment to inactivate
endogenous retroviruses in live immunological veterinary medicinal products
(EMA/CVMP/IWP/37924/2014). The current revision consists of administrative changes made in order
to align the reflection paper to Regulation (EU) 2019/6. As no changes were made to the scientific
content, no concept paper and no public consultation were deemed necessary.
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.
第 2 页
Reflection paper on the use of heat treatment to
inactivate endogenous retroviruses in live immunological
veterinary medicinal products (IVMPs)
Table of contents
Executive summary ..................................................................................... 3
1. Introduction ............................................................................................ 3
2. Scope....................................................................................................... 3
3. Background ............................................................................................. 4
4. Validation of the heat treatment ............................................................. 4
5. Possible impact of the heat treatment on the finished product................ 5
6. Requirements to demonstrate the absence of negative impact ............... 5
References .................................................................................................. 6
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in
live immunological veterinary medicinal products (IVMPs)
EMA/CVMP/IWP/37924/2014-Rev.1 Page 2/6
第 3 页
Executive summary
This reflection paper outlines the data requirements to be submitted by the marketing authorisation
holder (MAH) to introduce a heat treatment step to inactivate endogenous retroviruses in the active
substance during the production of live viral immunological veterinary medicinal products (IVMPs) and
to show the absence of negative impact of this treatment on the IVMP.
1. Introduction
Following the 2010 Journal of Virology publication [1] reporting the detection of retrovirus RD114 in
some live attenuated feline and canine vaccines commercially available in the EU and Japan, a
scientific assessment conducted by EMA/CVMP (EMA/CVMP/300321/2010) concluded that the presence
of replicative retrovirus RD114 in existing feline and canine vaccines due to the use of feline origin
starting materials (such as CrFK feline kidney cells, [2]) in their manufacturing processes could not be
ruled out.
The EMA/CVMP assessment considered that immediate regulatory action was not necessary, based on
the history of use of these vaccines in the EU to date (e.g. millions of doses administered over a
number of decades). The safety profile of authorised feline and canine vaccines was not considered to
have changed; rather, the issue related to improvements in detection methods for retroviruses (e.g.
use of molecular technologies). The benefit of the continued use of available vaccines against cat and
dog diseases was considered to clearly outweigh the risk linked to the potential presence of replicative
retrovirus RD114.
However, the IWP also considered a risk management strategy for already existing veterinary vaccines
in relation to RD114 and identified some actions in order to have on the market only feline vaccines
that have retroviral RD114 levels within an established acceptance limit, and, for canine vaccines, only
products that are free of replicative retrovirus RD114.
One of the actions concerns adjustments to the manufacturing processes so that the retroviral RD114
content of the currently authorised vaccines is within the acceptance limit (e.g. use of inactivation
steps/replacement of contaminated starting materials -e.g. seed materials, etc.). This document
outlines the requirements with regard to the inactivation process that may be used to inactivate
RD114. The requirements in this reflection paper are also considered to be applicable to the use of
heat treatment to inactivate endogenous retroviruses in general, in live viral vaccines.
2. Scope
The presence of RD114 retrovirus in vaccines is considered to be related to the use of starting
materials of feline origin (e.g. cells, viruses) in the manufacturing processes of feline and canine
vaccines.
A meeting was convened on 8 February 2013 with industry to discuss and understand practical
possibilities and proposals on how to reduce and/or to clear finished products of replicative competent
RD114 virus and the timing of introduction of any such proposals. One of the methods discussed at the
meeting was the use of the heat treatment to inactivate RD114 virus in live active substances.
Therefore, this document considers the possible use of heat treatment during production or at the
active substance level for the inactivation of replicative RD114 virus and, more generally, endogenous
retroviruses in live vaccines.
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in
live immunological veterinary medicinal products (IVMPs)
EMA/CVMP/IWP/37924/2014-Rev.1 Page 3/6
第 4 页
This document outlines the requirements that need to be fulfilled to show that there is no negative
impact of this treatment on the vaccine.
Before process changes, such as the introduction of a heat treatment step to remove/inactivate
retroviruses can be accepted, a standardised and validated detection assay needs to be developed, and
the acceptable limit for the relevant retroviral agent must be established (the term “limit” takes into
account the detection limit of the assay as well as the levels of the retroviral agent in current vaccines,
which to date are not considered to be associated with a significant risk).
3. Background
According to Annex II, Part IIIb.2C2.1. of Regulation (EU) 2019/6, ‘Seed materials, including cell seeds
and raw serum for anti-serum production shall be tested for identity and the absence of extraneous
agents shall be demonstrated according to the European Pharmacopoeia (…). If the presence of
extraneous agents is detected or suspected, the corresponding material shall be discarded or
processed to reduce the risk of presence with a validated treatment. If after treatment presence is
detected or suspected, the corresponding material shall be used only when further processing of the
product ensures their elimination and/or inactivation; elimination and/or inactivation of such
extraneous agents shall be demonstrated.’
4. Validation of the heat treatment
Objective of the study:
Define the parameters of the heat treatment step and provide evidence demonstrating that this
treatment will effectively inactivate replicative endogenous retroviruses.
Design of the study:
The active substance to be heat treated is spiked with a known amount of the live endogenous
retrovirus (e.g. RD114) or another relevant virus. The active substance should be produced in
accordance with the manufacturing process described in the marketing authorisation dossier. Once the
heat treatment has been applied, an assay for the amount of residual spiked retrovirus is performed.
The amount of retrovirus added to the active substance should be sufficiently high in order to
determine the ability of the heat treatment to effectively inactivate the virus and to allow calculation of
the reduction factor.
A validated quantitative infectivity assay should be used to determine the retrovirus titre before and
after the treatment.
Limits:
The method of quantification of the retrovirus should have adequate sensitivity and reproducibility and
should be performed with a sufficient number of repeated measurements to ensure statistical accuracy
of the results.
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in
live immunological veterinary medicinal products (IVMPs)
EMA/CVMP/IWP/37924/2014-Rev.1 Page 4/6
第 5 页
5. Possible impact of the heat treatment on the finished
product
It is assumed that the heat treatment is to be applied to the live active substance of the vaccine during
manufacture. The aim is to inactivate completely the replicative retrovirus with minimal impact on the
live active substance.
The heat treatment may potentially have different consequences:
- it may be necessary to increase the antigen content of the active substance in the finished product
as part of the live active substance may be inactivated during the heat treatment. In order to
comply with the specifications, the applicant may need to adjust the formulation to ensure the same
content of live active substance as in vaccine batches produced without the additional heat
treatment. In practice, this may result in a higher overall antigen content (consisting of a mixture of
live and inactivated antigens of the same active substance).
- it may lead to the selection of live virus variants (quasispecies) that are more resistant to heat, potentially
with different properties which then will be largely present in the finished product.
6. Requirements to demonstrate the absence of negative
impact
If the heat treatment is introduced into the production process, the marketing authorisation holder
must demonstrate that this treatment has no negative impact on the quality, safety and efficacy of the
finished product.
In order to demonstrate the absence of negative impact of the heat treatment, the following points
have to be considered:
- with regard to the quality of the finished product, except for the heat treatment and the possible
adjustment of the content of the live active substances in order to still comply with the authorised
specifications, the manufacturing process of the vaccine should not be modified unless adequately
justified and supported by appropriate data. The results of the titration of the live active substance
in the finished product shall remain within the range established for the untreated vaccine.
- with regard to the safety of the vaccine, the safety of an overdose of the heat-treated live active
substance must be demonstrated under laboratory conditions in compliance with the requirements
of Regulation (EU) 2019/6. Where the concerned active substance is part of a combined vaccine(s),
and the heat treatment does not require an increase of its antigen content, it is sufficient to
demonstrate the safety of a monovalent vaccine containing the heat-treated live active substance
under assessment. The results obtained should confirm that the vaccine containing the heat-treated
live active substance is safe for use.
- where the in vitro and manufacturing data generated to support the heat inactivation of the
retrovirus indicate that the heat treatment does not adversely affect the viability of the live
microorganism in the vaccine, and no adjustment of the manufacturing specifications is required,
confirmation of efficacy of the heat-treated active substance in the target species is not necessary.
Where there is any indication that the efficacy of the concerned active substance may be impacted,
the efficacy of the vaccine containing the heat-treated active substance has to be tested under
laboratory conditions according to the requirements of the immunogenicity test described in the
relevant Ph. Eur. monograph. The results should comply with the threshold defined in the
corresponding Ph. Eur. monograph.
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in
live immunological veterinary medicinal products (IVMPs)
EMA/CVMP/IWP/37924/2014-Rev.1 Page 5/6
第 6 页
If no Ph. Eur. monograph exists, the immunogenicity test should comply with the requirements of
the Ph. Eur. general monograph “Vaccines for veterinary use” and with the Ph. Eur. chapter 5.2.7
“Evaluation of efficacy of veterinary vaccines and immunosera”. The test should be the same as that
performed to demonstrate the efficacy of the active substance of the original vaccine and the
results obtained should be similar.
References
[1] Miyazawa T et al. Isolation of an infectious endogenous retrovirus in a proportion of live attenuated
vaccines for pets. J. Virol. 2010 Apr;84(7):3690-4.
[2] Baumann J et al. CrFK Feline Kidney Cells Produce an RD114-Like Endogenous Virus That Can
Package Murine Leukemia Virus-Based Vectors. J. Virol., 1998 Sep;72(9):7685-7687.
Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in
live immunological veterinary medicinal products (IVMPs)
EMA/CVMP/IWP/37924/2014-Rev.1 Page 6/6
来源:EMA Scientific Guidelines · ema.europa.eu